WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Google Secures Pentagon AI Deal for Classified Projects 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
NEWARK, Calif., Feb. 02, 2016 -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, today announced that Harold Van Wart, Ph.D., President and Chief Executive Officer, will present a corporate update at the BIO CEO & Investor Conference being held in New York on February 8-9.
| BIO CEO & Investor Conference – CymaBay Presentation Details | ||
| Date: | Tuesday, February 9 | |
| Time: | 1:30pm Eastern Time | |
| Place: | Waldorf-Astoria, New York, NY | |
| Webcast: | http://ir.cymabay.com/events | |
About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. Arhalofenate is a potential Urate-Lowering Anti-Flare Therapy that has completed five Phase 2 studies in gout patients. Arhalofenate has been found to reduce painful flares in joints while at the same time promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia. MBX-8025 is a potent, selective, orally active PPARδ agonist. A Phase 2 study of MBX-8025 in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. CymaBay has two ongoing clinical studies for MBX-8025 including a pilot Phase 2 study in patients with homozygous familial hypercholesterolemia and a Phase 2 study in patients with primary biliary cholangitis.
For additional information about CymaBay visit www.cymabay.com.
Sujal Shah CymaBay Therapeutics, Inc. (510) 293-8800 [email protected] Hans Vitzthum LifeSci Advisors, LLC 212-915-2568 [email protected]
